ViroPharma to Release 2008 Second Quarter Financial Results on Jul...( - Conference Call to Discuss R...),Health
Navigation Links
ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Date:7/14/2008
- Conference Call to Discuss Results to Be Held at 9:00 A.M. -
EXTON, Pa., July 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2008 are expected to be released on Wednesday, July 30, 2008 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2008 second quarter financial results and other business.
The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until August 15, 2008. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the
development and commercialization of products that address serious diseases
treated by physician specialists and in hospital settings. ViroPharma
commercializes Vancocin(R), approved for oral administration for treatment
of antibiotic-associated pseudomembranous colitis caused by Clostridium
difficile and enterocolitis caused by Staphylococcus aureus, including
methicillin- resistant strains (for prescribing information, please
download the package insert at http://www.viropharma.com/Products.aspx).
ViroPharma currently focuses it
'/>"/>
| SOURCE ViroPharma Incorporated Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
Post Your Comments:
(Date:12/4/2009)...Ariz., Dec. 4 Healthcare Trust of ... real estate investment trust, announced the execu... three building medical office portfolio located i...yne, Indiana for approximately $20,500,000. The c...action of a number of conditions. ,, The approx...
(Date:12/4/2009)... Dec. 4 In response to ...y,s (DEA) classification of boldione, desoxymethyl...e as "anabolic steroids", under the Controlled Sub...d CEO of the Natural Products Association (NPA), t...ing retailers and manufacturers of dietary supplem...
(Date:12/4/2009)... Americans are recruited annually to participate i...man Research Protection (AHRP), and most will be c...ch institutions view payments to volunteers as com...on for potential risks related to participating in...nteers have a very different view of clinical tria...
(Date:12/4/2009)...ure from federal regulators to crack down on abuse...4 (HealthDay News) -- The makers of 24 different p...l regulators with plans to curb the abuse of these...have been under pressure from U.S. Food and Drug A...hundreds of fatal overdoses that occur with these ...
(Date:12/4/2009)...-lowering drugs known as statins are among the mos... by researchers at Fred Hutchinson Cancer Research...ll transplant patients from one of the most seriou... graft-versus-host disease, or GVHD. The findings ...urnal Blood . , In a retrospective study of 567 ...
Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2[0] Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana[0] Natural Products Association Issues Statement on DEA's Steroid Classification Action[0] Human guinea pigs wary of high-paying medical trials[0] Makers of Powerful Painkillers Present Safety Plans [0] Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
...rastic reduction in chicken prices and public awar...ken back into the Indian menu//. A large number of...chicken, despite heath officials stating that well...he farmers, especially those with small holdings, ...
...AIDS awareness program, scheduled to take place in...es and plays//. The awareness programme would be t...tibility of the disease, particularly among young ...p of music bands like Euphoria and a band from Miz...
...ke University Medical Center have found that takin...ry artery disease increases the chances of dying./...risk of dying for patients who took such medicatio...ideration.
"This finding that antidepressant u...
...ion system for junior doctor posts is not in the i...job prospects of many top students. This was the o...
The system being followed is the “Modernisin...med by specialists is that the process is untested...
...ted on Remicade (infliximab) showed rapid, signifi...re plaque psoriasis. The stud mainly used placebo-...kg. The continuous eight week maintenance therapy ... patients treated with Remicade 3 mg/kg and 75 % o...
...' warn consumers on how to spot the misleading pro...y and nutritional HGH products.//
Various sp...product manufacturers, distributors, or resellers ....net), representing 17,500 physicians in 86 nation...
Other Medicine News:Health News:Poultry Industry In India Suffers A Set Back 2Health News:Music Helps in Spreading AIDS Awareness 2Health News:Online recruitment criticised by doctors 2Health News:Beware Of Bogus Claims by HGH Spray Internet Marketers 2Health News:Beware Of Bogus Claims by HGH Spray Internet Marketers 3Poultry Industry In India Suffers A Set BackMusic Helps in Spreading AIDS AwarenessHeart Patients Taking Anti-depressants Have Higher Risk Of DeathOnline recruitment criticised by doctorsRemicade Emerges as a Treatment for Patients Suffering From Psoriasis DisorderBeware Of Bogus Claims by HGH Spray Internet Marketers
(Date:12/4/2009)... CITY, Dec. 4 Dynatronic...gned a sole-source vendor agreement to provide the...sical Therapy with 65 clinics located in Tennessee...he sole-source supplier to Benchmark Physical Ther...dent of sales and marketing at Dynatronics. "Bench...
(Date:12/4/2009)..., WASHINGTON, Dec. 4 ...rt published by the Pharmaceutical Research and ...s 97 new drugs and vaccines in development for HIV... found that the 97 products in development includ...ither in human clinical trials or awaiting approva...
(Date:12/4/2009)... Md., Dec. 4 PharmAthene...veloping medical countermeasures against biologica...ompany is presenting results of a study demonstrat...lation anthrax model in the New Zealand White (NZW...oral session at the HHS Public Health Emergency Me...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6New material for nanoscale computer chips 13620 1New material for nanoscale computer chips 13620 2Alternative Therapies And Their Growing Popularity 54813 1Alternative Therapies And Their Growing Popularity 54813 2Alternative Therapies And Their Growing Popularity 54813 3Alternative Therapies And Their Growing Popularity 54813 4Induced Labor May Prevent Need for Cesarean Section 54811 1Induced Labor May Prevent Need for Cesarean Section 54811 2...d that the U.S. Food and Drug Administration (FDA)... for the Biologics License Application (BLA) for A...IL-6) receptor-inhibiting monoclonal antibody stud...ately to severely active rheumatoid arthritis (RA)... Evaluation and Mitigation Strategy (REMS) require...
...amp; Lymphoma Society (LLS) and Memgen, LLC jointl...f ISF35, a cancer vaccine, at the University of C...llaborating on this trial in the hopes that it wil...proach aimed at treating patients with fludarabine... leukemia (CLL). , , Doctors at UCSD have al...
Other Medicine Technology:Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |